**Core Concept**
Somatostatin is a peptide hormone that regulates various physiological processes, including glucose and lipid metabolism. However, its primary role is as a hormone that inhibits the release of other hormones, rather than directly affecting lipid levels.

**Why the Correct Answer is Right**
Somatostatin does not have a direct effect on lipid metabolism, unlike the other options listed. It primarily acts by inhibiting the release of growth hormone, thyroid-stimulating hormone, and other hormones involved in metabolic regulation. While somatostatin may indirectly affect lipid metabolism by influencing hormone release, it is not a primary choice for treating lipid disorders.

**Why Each Wrong Option is Incorrect**
**Option A:** Simvastatin is a statin, a class of drugs that inhibit HMG-CoA reductase, a key enzyme in cholesterol synthesis, making it a hypolipidemic agent.
**Option B:** Fenofibrate is a fibric acid derivative, which activates peroxisome proliferator-activated receptor-alpha (PPAR-alpha), leading to increased lipolysis and decreased triglyceride levels, thus acting as a hypolipidemic agent.
**Option D:** Fluvastatin is another statin that inhibits HMG-CoA reductase, making it a hypolipidemic agent.

**Clinical Pearl / High-Yield Fact**
When considering lipid-lowering therapy, it's essential to choose a medication that targets the underlying pathophysiology of the patient's lipid disorder. Statins and fibrates are commonly used, but somatostatin is not a primary choice due to its indirect effects on lipid metabolism.

**✓ Correct Answer: C. Somatostatin**